Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria Victoria Costanzo"'
Autor:
Maria del Rosario Sifón, Nicolas Marcolini, Maria Julia Barber, Ignacio Mclean, Manglio Rizzo, Sergio Rivero, Maria Victoria Costanzo, Adrian Nervo, Gabriel Crimi, Florencia Perazzo, Estrella Mariel Levy, Pablo Mandó
Publikováno v:
Breast Care. 17:546-553
Background: Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe2be6820d9e2e98978f7a693ee8ae3
https://doi.org/10.1159/000525287
https://doi.org/10.1159/000525287
Autor:
Laura Sabina Lapuchesky, Marcos Bortz, Federico Waisberg, Diego Hernán Enrico, Luisina Ines Bruno, Cristian Alexis Ostinelli, Sergio Gabriel Rivero, Andres Rodriguez, Martin Zarba, Martin Loza, Verónica Yamila Fabiano, Mora Amat, Maria Teresa Pombo, Maria Laura Noro, Federico Andrés Coló, Reinaldo D. Chacon, Matias Rodrigo Chacon, Jorge Carlos Nadal, Adrian Nervo, Maria Victoria Costanzo
Publikováno v:
Journal of Clinical Oncology. 40:1056-1056
1056 Background: HER2-low expression, defined as HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization assay (FISH), accounts for 50% of breast cancers. There is limited and conflicting evidence regarding the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40928805b4032cd3b49c6a1c1e1e1d2
https://doi.org/10.1200/jco.2022.40.16_suppl.1056
https://doi.org/10.1200/jco.2022.40.16_suppl.1056
Autor:
Ayelén Ivana Pesce Viglietti, María Belén Bordignon, Alexis Ostinelli, Manglio Miguel Rizzo, Gerardo Cueto, María Belén Sanchez, Florencia Perazzo, Mora Amat, Federico Coló, María Victoria Costanzo, Adrián Nervo, Jorge Nadal, Gabriel Crimi, Ignacio Mc Lean, Eunice Amancay Spengler, José Mordoh, Pablo Mandó, Estrella Mariel Levy
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 17, p 9268 (2024)
Currently, therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is based on the combination of trastuzumab and pertuzumab plus chemotherapy in a neoadjuvant regimen. The INMUNOHER study aimed to detect
Externí odkaz:
https://doaj.org/article/d6c1e774ca4b49c8941b609b2ef344a6
Autor:
Carolina Ponce, Verónica Fabiano, Constanza Pérez de la Puente, Maria Victoria Costanzo, Mora Amat, Federico Coló, Manglio Rizzo, Chacon Reinaldo, Pablo Mandó, Carlos Martin Loza, Jorge Nadal, Maria Teresa Pombo, Adrian Nervo, M Maino, Jose Loza
Publikováno v:
Journal of Breast Cancer
Purpose Several studies have shown that estrogen receptor (ER) and progesterone receptor (PR) expression and human epidermal growth factor receptor 2 (HER2) expression may vary during tumoral progression. We aimed to describe and compare ER, PR, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc553e2adf2df7d6c7e5a6793f50a6c
https://doi.org/10.4048/jbc.2017.20.2.170
https://doi.org/10.4048/jbc.2017.20.2.170
Autor:
Verónica Fabiano, Pablo Mandó, Manglio Rizzo, Carolina Ponce, Federico Coló, Martín Loza, Jose Loza, Mora Amat, Daniel Mysler, María Victoria Costanzo, Adrián Nervo, Jorge Nadal, Florencia Perazzo, Reinaldo Chacón
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 639-646 (2020)
PURPOSE Multiple studies have reported that breast cancer in young patients is associated with aggressive characteristics, and it is suggested that prognosis is worse independently of pathologic variables. PATIENTS AND METHODS We performed a retrospe
Externí odkaz:
https://doaj.org/article/bd68930b829f4c82925e350c5f266a10